[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …
…, B Johnson, D Johnson, K Kerr, K Kuriyama… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
[HTML][HTML] The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification
…, K Geisinger, FR Hirsch, Y Ishikawa, KM Kerr… - Journal of thoracic …, 2015 - Elsevier
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura,
Thymus and Heart has just been published with numerous important changes from the 2004 …
Thymus and Heart has just been published with numerous important changes from the 2004 …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer,
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …
and deaths from lung cancer exceed those from any other malignancy worldwide [1]. In …
[HTML][HTML] Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer
…, JR Brahmer, SJ Swanson, K Kerr… - … England Journal of …, 2022 - Mass Medical Soc
Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-…
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-associated
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …
antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand PD-L1 …
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
…, G Langman, S Trotter, M Nicolson, H Remmen, K Kerr… - Nature, 2017 - nature.com
The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …
the characterization of emerging subclones, which seed metastatic sites, might offer new …
[HTML][HTML] Tracking the evolution of non–small-cell lung cancer
…, S Trotter, M Nicolson, H Remmen, K Kerr… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …
[PDF][PDF] Allele-specific HLA loss and immune escape in lung cancer evolution
…, K Kerr, S Palmer, H Remmen, J Miller, K Buchan… - Cell, 2017 - cell.com
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …
[HTML][HTML] Interoception and mental health: a roadmap
Interoception refers to the process by which the nervous system senses, interprets, and
integrates signals originating from within the body, providing a moment-by-moment mapping of …
integrates signals originating from within the body, providing a moment-by-moment mapping of …
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are still …